TABLE 2.
Secondary prevention medications and lipid levels during the chronic phase (median 11.1 months after the index event)
| All patients (n = 3789) | REDUCE‐IT‐Excluded (n = 3317) | REDUCE‐IT‐Like (n = 472) | P value | |
|---|---|---|---|---|
| Selected cardiac medications | ||||
| Statin | 3314 (87.5%) | 2842 (85.7%) | 472 (100.0%) | – |
| Statin intensity among those on a known‐dose statin | – | – | – | 0.03 |
| Low dose a | 80/3309 (2.4%) | 69/2837 (2.4%) | 11/472 (2.3%) | – |
| Moderate dose b | 898/3309 (27.1%) | 746/2837 (26.3%) | 152/472 (32.2%) | – |
| High dose c | 2331/3309 (70.4%) | 2022/2837 (71.3%) | 309/472 (65.5%) | – |
| Ezetimibe | 210 (5.5%) | 169 (5.1%) | 41 (8.7%) | .001 |
| Beta‐blocker | 3065 (80.9%) | 2656 (80.1%) | 409 (86.7%) | .001 |
| ACE inhibitor or angiotensin II receptor blocker | 3366 (88.8%) | 2923 (88.1%) | 443 (93.9%) | <.001 |
| Antiplatelet | 3585 (94.6%) | 3130 (94.4%) | 455 (96.4%) | .07 |
| Lipid values (mg/dL) | ||||
| Triglycerides, median (IQR) | 104 (77‐143) | 96 (74‐125) | 192 (166‐235) | <.001 |
| Total cholesterol, mean ± SD | 160 ± 53 | 161 ± 54 | 159 ± 41 | .43 |
| HDL‐C, mean ± SD | 52 ± 27 | 53 ± 27 | 43 ± 23 | <.001 |
| LDL‐C, mean ± SD | (n = 3728) 85 ± 37 | (n = 3272) 86 ± 39 | (n = 456) 72 ± 16 | <.001 |
| Triglycerides >200 mg/dL + HDL‐C < 35 mg/dL | 147 (3.9%) | 71 (2.1%) | 76 (16.1%) | <.001 |
Note: Data given as number (%), n/N (%), mean ± SD or median (IQR).
Abbreviations: HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; REDUCE‐IT, reduction of cardiovascular events with icosapent ethyl‐intervention trial.
a
Low dose: simvastatin 10 mg/d, pravastatin 10‐20 mg/d, or fluvastatin 20‐40 mg/d.
b
Moderate dose: atorvastatin 10‐20 mg/d, rosuvastatin 5‐10 mg/d, simvastatin 20‐40 mg/d, pravastatin 40 mg/d, or fluvastatin 80 mg/d.
c
High dose: atorvastatin 40‐80 mg/d or rosuvastatin 20‐40 mg/d.